News Headlines

  1. Roivant Announces Development Of Anti-GM-CSF Monoclonal Antibody To Prevent And Treat Acute Respiratory Distress Syndrome (ARDS) In Patients With COVID-19 3/18/2020

    Roivant Sciences today announced that it has engaged with regulators in the United States, Europe, and Asia to rapidly advance the clinical development of gimsilumab for the treatment of acute respiratory distress syndrome (ARDS) associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

  2. Bora's responsibility To navigate COVID-19 3/16/2020

    As the world is fighting to contain the COVID-19 (the coronavirus), I wanted to reach out and provide an update on the actions that Bora is taking to prevent the spread of the virus, ensure business continuity, and support the health and well-being of our customers, employees and communities.

  3. Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization To Thermo Fisher 3/13/2020

    Today, the U.S. Food and Drug Administration took another significant diagnostic action during the coronavirus outbreak (COVID-19)

  4. FUJIFILM Diosynth Biotechnologies Breaks Ground On A New Biocampus At Its Billingham, UK Location 3/12/2020

    FUJIFILM Diosynth Biotechnologies (FDB), a world leading cGMP Contract Development and Manufacturing Organization (CDMO) supporting its partners in the biopharmaceutical industry with the development and production of their biologics, vaccines and gene therapies, held a ground breaking ceremony on March 10, 2020 signalling commencement of construction of the company’s new BioCampus at its Billingham, UK location.

  5. AbCellera And Lilly To Co-Develop Antibody Therapies For The Treatment Of COVID-19 3/12/2020

    AbCellera and Eli Lilly and Company (NYSE: LLY) announced today they have entered into an agreement to co-develop antibody products for the treatment and prevention of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus

  6. BD Completes Clinical Trial For BD Libertas Wearable Injector 3/11/2020

    BD (Becton, Dickinson and Company), a leading global medical technology company, today announced the completion of a 50-subject human clinical trial with the BD Libertas Wearable Injector.

  7. Bora Pharmaceuticals To Acquire GSK Mississauga-Based Facility 3/9/2020

    Bora Pharmaceuticals Co., Ltd  (6472.TWO) and GSK announced today they have entered into an agreement under which Bora Pharmaceuticals will acquire GSK's Mississauga, Ontario (Canada) facility. 

  8. DCAT Week 2020 Cancelled Due To COVID-19 Concerns 3/6/2020

    The DCAT organization has been following the situation around COVID-19 very closely. While we recognize and appreciate how important this event is to our member companies, out of an abundance of caution, and with a rapidly growing number of our participants not being able to travel, we’ve made the difficult decision to cancel DCAT Week 2020.

  9. JSR Life Sciences Company KBI Biopharma, Inc. Promotes Dirk Lange To CEO 3/2/2020

    JSR Life Sciences, LLC announced today that Dirk Lange will take over as president and chief executive officer of KBI Biopharma, Inc., a leading contract development and manufacturing organization (CDMO) and JSR Life Sciences affiliate company.

  10. Seikagaku Announces Acquisition (Incorporation As A Subsidiary) Of Dalton Chemical Laboratories, Inc. Of Canada 2/28/2020

    Seikagaku Corporation (Tokyo, Japan; “Seikagaku”) announces that it has resolved at a Board of Directors meeting on February 21, 2020, through use of a special purpose acquisition company, to make a cash acquisition of all shares outstanding of Dalton Chemicals Laboratories, Inc., (Toronto, Canada; "Dalton") an unlisted company in Canada.